Q-omics provides the consensus-scored HLA-DPA2 profile across patient tissues and cancer cell-line models. HLA-DPA2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HLA-DPA2 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, HLA-DPA2 RNA expression shows 6,117 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, LUSC, and STAD as cancer lineages where HLA-DPA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HLA-DPA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HLA-DPA2 survival associations across molecular data types. HLA-DPA2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HLA-DPA2 RNA expression–survival associations across cancer types. High HLA-DPA2 expression shows unfavorable associations in KIRC, THCA and LIHC, but favorable associations in SKCM, CHOL and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for HLA-DPA2 RNA expression.
This table summarizes HLA-DPA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for HLA-DPA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HLA-DPA2 shows lower tumor expression in LUSC, COAD and THCA and higher tumor expression in STAD. The LUSC box plot shows higher HLA-DPA2 RNA expression in normal versus tumor tissue (log2 FC = −0.054, t-test p = .007).
This table shows molecular features associated with HLA-DPA2 in patient tissues and cancer cell lines. In patient samples, HLA-DPA2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
